KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbCellera Biologics (ABCL) Debt to Equity (2020 - 2025)

AbCellera Biologics filings provide 6 years of Debt to Equity readings, the most recent being $0.01 for Q1 2025.

  • Quarterly Debt to Equity fell 81.16% to $0.01 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $0.01 through Mar 2025, down 81.16% year-over-year, with the annual reading at $0.01 for FY2024, 82.52% down from the prior year.
  • Debt to Equity hit $0.01 in Q1 2025 for AbCellera Biologics, up from $0.01 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.05 in Q2 2023 and bottomed at $0.01 in Q4 2024.
  • Average Debt to Equity over 5 years is $0.03, with a median of $0.02 recorded in 2022.
  • The largest annual shift saw Debt to Equity soared 136.16% in 2022 before it plummeted 82.52% in 2024.
  • AbCellera Biologics' Debt to Equity stood at $0.02 in 2021, then soared by 60.33% to $0.04 in 2022, then grew by 22.19% to $0.04 in 2023, then plummeted by 82.52% to $0.01 in 2024, then grew by 11.97% to $0.01 in 2025.
  • Per Business Quant, the three most recent readings for ABCL's Debt to Equity are $0.01 (Q1 2025), $0.01 (Q4 2024), and $0.02 (Q3 2024).